January 5, 2022: The Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission recently updated several sections of the Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. The following sections were among those updated:

• Maternal HIV Testing and Identification of Perinatal HIV Exposure
• Pre-Exposure Prophylaxis (PrEP) to Prevent HIV During Periconception, Antepartum, and Postpartum Periods
• Reproductive Options for Couples When One or Both Partners Have HIV
• Recommendations for Use of Antiretroviral Drugs During Pregnancy
• Pregnant People with HIV Who Are Currently Receiving Antiretroviral Therapy
• Acute HIV
• Perinatal HIV Prevention for Transgender and Gender Diverse People Assigned Female Sex at Birth
• Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection

Visit the What’s New in the Guidelines page for a full summary of the changes. The revisions to the perinatal treatment guidelines were made by the Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission (a Working Group of the National Institutes of Health Office of AIDS Research Advisory Council).